Document Type : Original Article
Authors
1 Solid Tumor Research Center, Urmia University of Medical Sciences, Urmia, Iran
2 Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
3 Hematology, Immune Cell Therapy, and Stem Cells Transplantation Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran
Abstract
Background: Survival studies are needed in patients with cutaneous malignant melanoma (CMM) due to the growing incidence trend worldwide. We aimed to determine the survival trend in patients suffering from CMM, considering various demographic and tumor characteristics.
Methods: In this descriptive-analytical study, we examined 57 patients with confirmed melanoma from April 2014 to February 2019. Using the Kaplan-Meier method and log-rank test, we assessed the correlation between survival probability and factors with prognostic potential, such as gender, age, tumor thickness, mitotic rate, anatomical sites, and chemotherapy.
Results: Out of 57 patients with a mean age of 59.5 ± 22.7 years, 33 (57.9%) were females. The mean survival was 43 ± 15 months, ranging from 15 to 82 months. Regarding tumor thickness, 26 patients had 1–4 mm tumor thickness, 18 patients 5–10 mm, and five patients 11–30 mm. The tumor mitotic rate was 1–2 mitoses/ mm2 in 19 patients and ≥ 3 mitoses/mm2 in 32 patients. Infiltrated lymphocytes were present in 36 patients (36.6%). In the case of therapeutic intervention, 55 patients received chemotherapy. According to the results of the Kaplan-Meyer test, the mean survival did not show a significant difference (P < 0.05) in patient subgroups. Moreover, a profound correlation was not found between survival rate and different age groups, mitotic rate, thickness, lymphocyte infiltration, and chemotherapy.
Conclusion: Irrespective of disease stage and histopathology examination, we found no significant correlation between survival rate and demographic/tumor characteristics in patients with CMM.
Keywords
)